My Size, Inc.

Where It Passes

Where It Falls Short

• Valuation0% pass✓ 9✗ 19▾

  No clean pass — all 13 investors flag at least one valuation criterion

  Price / 3-yr avg EPS

  ✗Graham<= 15x

  Price-to-Book Ratio0.6x

  ✓Graham<= 1.5x

  P/E x P/B

  ✗Graham<= 22.5

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  EBIT / Enterprise Value-542.7%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-542.7%, ROC=-892.7%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Price / EPS

  ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)

  Price / (CFO / Shares)N/A (negative CFPS)

  ✗Dreman< 8x

  Price / Book Value per Share0.6x

  ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)

  Valuation Reasonableness

  ✗MungerP/E < 25 or Owner Earnings Yield > 5%

  P/E or FCF YieldFCF Yield=-642.6%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  P/B or P/E vs. Historical AverageP/B=0.6x

  ✓MarksP/E < 15 or P/B < 2.0

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Price / FCF per ShareN/A (negative FCF)

  ✗Ackman<= 25

  Price vs. Trailing Low100% of trailing low ($0.68)

  ✓Templeton<= 120% of trailing low (certified split-adjusted live window)

  Net income / market capitalization-943.11%; #6056/6340 (top 95.5%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Positive book equity / market capitalization+2.9240; #467/6449 (top 7.2%)

  ✓AsnessTop 30% of eligible cross-section

  Price / Diluted EPS

  ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)

  (EPS CAGR % + Dividend Yield %) / P/E

  ✗Neff> 0.7 (Neff's published traditional edge)

  Price / Tangible Book Value per Share1.08x

  ✗SchlossP/TBV <= 1.00x (app cutoff)

  Book Value per Share Change+287.2%

  ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)

  Revenue / market capitalization+14.1292; #256/5247 (top 4.9%)

  ✓OshaughnessyTop 10% of eligible cross-section

  (Operating cash flow - capex) / market capitalization-613.83%; #4370/4519 (top 96.7%)

  ✗OshaughnessyTop 10% of eligible cross-section

  Trailing six-month price return through the evaluation date-86.96%; #5946/6202 (top 95.9%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Cash Flow0% pass✓ 1✗ 11▾

  No clean pass — all 10 investors flag at least one cash flow criterion

  Free Cash Flow Proxy

  ✗BuffettPositive and growing

  FCF Positive and Growing$-5.2M

  ✗LynchPositive and growing

  Operating Cash Flow$-5.1M

  ✗PiotroskiCFO > 0

  (CFO / Total Assets) vs ROACFO/Assets=-50.39%, ROA=-57.35%

  ✓PiotroskiCFO/Assets > ROA

  Price / (CFO / Shares)N/A (negative CFPS)

  ✗Dreman< 8x

  P/E or FCF YieldFCF Yield=-642.6%

  ✗PabraiP/E < 15 or FCF Yield > 10%

  FCF Positive0/12 years FCF positive

  ✗MarksPositive FCF in majority of recent years

  (OCF - CapEx) / Market Cap-156.2%

  ✗Ackman>= 4%

  Price / FCF per ShareN/A (negative FCF)

  ✗Ackman<= 25

  Positive Operating Cash Flow frequency0/14 years positive

  ✗SleepPositive OCF in >= 70% of available years

  Operating Cash Flow - Capital Expenditures$-4.9M

  ✗Neff> $0 (app proxy for a strong fundamental case)

  (Operating cash flow - capex) / market capitalization-613.83%; #4370/4519 (top 96.7%)

  ✗OshaughnessyTop 10% of eligible cross-section
• Efficiency0% pass✓ 1✗ 10▾

  No clean pass — all 8 investors flag at least one efficiency criterion

  Current Ratio1.29

  ✗Graham>= 2.0

  ROIC (3-5 yr avg)-163.2%

  ✗Buffett> 10%

  ROIC - WACC-173.2%

  ✗BuffettPositive (WACC = 10%)

  EBIT / (NWC + Net Fixed Assets)-892.7%

  ✗Greenblatt> 25%

  Current Ratio Change YoY3.03 -> 1.87

  ✗PiotroskiIncreased YoY

  Revenue / Total Assets Change YoY0.82x -> 0.92x

  ✓PiotroskiImproved YoY

  Current Assets / Current Liabilities1.29

  ✗Dreman> 1.5

  Return on Invested Capital-171.4%

  ✗Munger> 15%

  ROIC (high and growing)FY2023: ROIC=-103.6%; FY2024: ROIC=-43.5%; FY2025: ROIC=-74.6%

  ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each

  Reinvestment Rate x ROICN/A (non-positive net income)

  ✗AkreReinvestment Rate * ROIC > 10%

  ROIC (5-year)0/4 years above 12% (latest -74.6%)

  ✗SleepROIC > 12% in a majority of years
• Verdicts13% pass✓ 2✗ 13▾

  Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL

  Overall verdict

  ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #3065✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✓AckmanPASS (4/9)•TempletonNEUTRAL (5/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #2100/2370 (Top 88.6%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
• Profitability19% pass✓ 7✗ 28▾

  13 of 16 flag MYSZ's profitability — Graham, Buffett, Lynch +10 more

  Positive EPS (10 years)4/18 years positive

  ✗GrahamPositive EPS every year for 10 years

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Net Income Positive (10+ years)0/18 years positive

  ✗BuffettPositive every year for 10+ years

  ROE (up to 5-year arithmetic mean)-117.2%

  ✗Buffett> 15% arithmetic mean (app rule)

  Operating Margin (10-yr trend)-61.3% (latest)

  ✓BuffettStable or rising over 10 years

  Free Cash Flow Proxy

  ✗BuffettPositive and growing

  Earnings Variance (10-yr CoV)N/A (negative mean EPS)

  ✗BuffettCoV < 0.3

  Retained Earnings Effectiveness

  ✗Buffett$1 retained -> > $1 market value created

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  ROE-322.5%

  ✗Lynch> 15%

  EBIT / Enterprise Value-542.7%

  ✗Greenblatt> 10%

  Earnings Yield + ROC AssessmentEY=-542.7%, ROC=-892.7%

  ✗GreenblattBoth EY > 10% and ROC > 25%

  Net Income / Total Assets-57.35%

  ✗PiotroskiROA > 0

  ROA Change YoY-39.72% -> -57.35% (delta: -17.63%)

  ✗PiotroskiCurrent ROA > Prior ROA

  (CFO / Total Assets) vs ROACFO/Assets=-50.39%, ROA=-57.35%

  ✓PiotroskiCFO/Assets > ROA

  Gross Margin Change YoY40.2% -> 32.0%

  ✗PiotroskiImproved YoY

  Pre-Tax Income / Revenue-66.7%

  ✗Dreman>= 8%

  Net Income / Shareholders' Equity-322.5%

  ✗Dreman> 12%

  Margin of SafetyP/B=0.6x

  ✓PabraiP/B < 1.5 or P/E < 15

  Return on Equity-102.0% (3-yr avg)

  ✗AkreROE > 20% (3-year avg)

  Discount to Intrinsic ValueN/A (negative normalized EPS)

  ✗Marks>= 20% below intrinsic value

  Positive Net Income Frequency0/17 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  Operating Income / Revenue-63.7%

  ✗Ackman>= 15%

  Net Income / Shareholders Equity-322.5%

  ✗Ackman>= 15%

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Operating Margin Trend-96.4% (2023) -> -61.3% (2025)

  ✓TempletonNon-negative operating-margin trend over 3 years

  Revenue growth vs. gross and operating margin trendgross margin 39.0% -> 32.0%, operating margin -96.4% -> -61.3%

  ✓SleepRevenue rising; gross margin flat or falling; operating margin holding

  Net income / market capitalization-943.11%; #6056/6340 (top 95.5%)

  ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section

  Gross profit / total assets+51.97%; #626/3702 (top 16.9%)

  ✓AsnessTop 30% of eligible cross-section

  Net income / positive book equity-322.54%; #4998/5226 (top 95.6%)

  ✗AsnessTop 30% of eligible cross-section

  Negative 5-year standard deviation of ROA-0.1717; #4066/5884 (top 69.1%)

  ✗AsnessTop 30% of eligible cross-section

  3-5 Year Diluted EPS CAGR8.4% over 5 years

  ✓Neff7%-20% annualized

  Positive Diluted-EPS Years0/10 years positive

  ✗Schloss>= 70% positive over 5-10 observed years (app rule)
• Debt & Leverage33% pass✓ 6✗ 9▾

  8 of 12 flag MYSZ's debt & leverage — Buffett, Lynch, Piotroski +5 more

  Debt Levels0.42

  ✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3

  LT Debt vs Net Current AssetsLT Debt $0.8M vs NCA $1.0M

  ✓GrahamLT Debt <= Net Current Assets

  Debt/Equity & Interest CoverageD/E: 0.18, IC: N/A

  ✗BuffettD/E < 0.5 AND Interest Coverage > 5x

  Total Debt / Equity0.42

  ✗Lynch< 0.33

  Cash - Long-term Debt$-0.3M

  ✗LynchPositive preferred

  LT Debt / Total Assets Change1.45% -> 8.14%

  ✗PiotroskiDecreased YoY

  Current Assets / Current Liabilities1.29

  ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)

  Total Debt / Shareholders' Equity0.42

  ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x

  Interest Coverage & Debt/EBITDA

  ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x

  Total Debt / Shareholders Equity0.42

  ✓Ackman<= 1.0

  Negative debt-to-equity (higher means less debt)-0.4180; #2283/4210 (top 54.2%)

  ✗AsnessTop 30% of eligible cross-section
• Growth38% pass✓ 7✗ 6▾

  5 of 8 flag MYSZ's growth — Graham, Lynch, Dreman +2 more

  EPS Growth (3-yr avg, 10-yr window)

  ✗Graham>= 33% growth

  Basic earnings-growth PEG (dividends excluded)

  ✗Lynch< 1.0 (ideally < 0.5)

  3-5 Year EPS CAGR

  ✗Lynch15-30% (Fast Grower); > 0% to pass

  Inventory Growth vs Revenue GrowthInv: -32.4% vs Rev: 67.3%

  ✓LynchInventory growth < Revenue growth

  EPS Growth Direction$0.15 (2010) -> $-1.87 (2025)

  ✗DremanPositive over recent years

  EPS CAGR8.4% CAGR over 5 years

  ✓Dreman> 5% annualized

  Positive Net Income Frequency0/17 years positive

  ✗MarksPositive net income in >= 7 of last 10 years

  3yr Median Revenue Growth18.0%

  ✓Ackman>= 5%

  Positive EPS Growth Frequency3/5 years with positive EPS growth

  ✓AckmanPositive EPS growth in >= 3 of last 5 years

  5-Year EPS CAGR

  ✗Templeton> 0% (5-year EPS CAGR)

  Revenue growth vs. gross and operating margin trendgross margin 39.0% -> 32.0%, operating margin -96.4% -> -61.3%

  ✓SleepRevenue rising; gross margin flat or falling; operating margin holding

  5-year Revenue CAGR131.1%

  ✓SleepCAGR > 7%

  3-5 Year Diluted EPS CAGR8.4% over 5 years

  ✓Neff7%-20% annualized